Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,940,881
  • Shares Outstanding, K 25,007
  • Annual Sales, $ 8,550 K
  • Annual Income, $ -182,820 K
  • EBIT $ -293 M
  • EBITDA $ -298 M
  • 60-Month Beta 2.80
  • Price/Sales 545.05
  • Price/Cash Flow N/A
  • Price/Book 11.49

Options Overview Details

View History
  • Implied Volatility 124.72% (+5.23%)
  • Historical Volatility 306.38%
  • IV Percentile 64%
  • IV Rank 32.72%
  • IV High 241.91% on 02/07/25
  • IV Low 67.73% on 10/22/25
  • Expected Move (DTE 3) 15.54 (8.04%)
  • Put/Call Vol Ratio 12.96
  • Today's Volume 1,326
  • Volume Avg (30-Day) 1,748
  • Put/Call OI Ratio 1.74
  • Today's Open Interest 30,015
  • Open Int (30-Day) 27,634
  • Expected Range 177.81 to 208.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.00
  • Number of Estimates 8
  • High Estimate -2.17
  • Low Estimate -3.45
  • Prior Year -2.94
  • Growth Rate Est. (year over year) -2.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
154.45 +25.35%
on 11/05/25
206.71 -6.34%
on 10/30/25
+3.61 (+1.90%)
since 10/17/25
3-Month
37.19 +420.57%
on 09/08/25
206.71 -6.34%
on 10/30/25
+146.97 (+315.18%)
since 08/18/25
52-Week
26.70 +625.09%
on 04/09/25
206.71 -6.34%
on 10/30/25
+122.09 (+170.73%)
since 11/18/24

Most Recent Stories

More News
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 187.86 (-4.92%)
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

PRAX : 187.86 (-4.92%)
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide HCl in essential tremor (ET); Pre-NDA meeting with FDA scheduled for Q4 2025 Plans to accelerate the development...

PRAX : 187.86 (-4.92%)
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback

Comprehensive meeting with FDA conducted in Q3 in conjunction with Breakthrough Therapy Designation Key aspects of a potential NDA application discussed and aligned with the Agency Praxis plans...

PRAX : 187.86 (-4.92%)
LifeSci Capital Keeps Their Buy Rating on Praxis Precision Medicines (PRAX)

LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Praxis Precision Medicines today and set a price target of $373.00. The company’s shares opened today at $158.29.Elevate Your Investing...

PRAX : 187.86 (-4.92%)
Praxis Precision Medicines Announces Positive Phase 3 Results

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

PRAX : 187.86 (-4.92%)
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 187.86 (-4.92%)
Stock Indexes Fall as Regional Bank Stocks Plunge

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.36%. December...

ANET : 124.62 (-2.07%)
B : 38.03 (+2.90%)
WAL : 74.79 (+1.26%)
CFG : 50.45 (+1.49%)
HBAN : 15.39 (+0.59%)
ADI : 230.88 (+0.41%)
SNA : 330.18 (+0.45%)
GFI : 40.24 (+2.37%)
$IUXX : 24,639.25 (-0.65%)
FFIV : 228.81 (+0.07%)
ZNZ25 : 112-240 (+0.10%)
TFC : 44.46 (+1.23%)
Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...

PRAX : 187.86 (-4.92%)
This ‘Strong Buy’ Stock Has More Than Tripled Today. Should You Buy It Here?

Praxis shares soar as the biotech firm reports promising late-stage results for ulixacaltamide. Here’s why it may not be too late to invest in PRAX shares.

PRAX : 187.86 (-4.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Praxis Precision Medicines Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis Precision Medicines Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 215.33
2nd Resistance Point 206.88
1st Resistance Point 202.23
Last Price 187.86
1st Support Level 189.13
2nd Support Level 180.67
3rd Support Level 176.02

See More

52-Week High 206.71
Last Price 187.86
Fibonacci 61.8% 137.95
Fibonacci 50% 116.71
Fibonacci 38.2% 95.46
52-Week Low 26.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar